AbbVie Stock Prediction and Forecast [ABBV]

AI-generated source summary

This technical analysis of AbbVie (ABBV), published on August 27, 2025, identifies a robust short-term upward trend, estimating an 11.13% change over the upcoming three months with returns ranging from 3.58% to 13.2%. Long-term 12-month outlook predicts approximately 3.08% price appreciation with fluctuations between -15.74% and 8.88%, projecting a future price range of $175.31 to $226.53. The latest daily update on August 27, 2025, shows ABBV's stock price decreasing by 0.144%, fluctuating by 1.26% between a low of $207.81 and a high of $210.42, with a 3 million share volume. Our systems indicate undervaluation and ABBV as a 'Buy Candidate' with signals suggesting further declines until a new bottom pivot is found, a stop loss is suggested at $199.92. It emphasizes the significance of monitoring the upcoming earnings report for the third quarter of 2025.The report notes a recent insider purchase of 42,370 shares and a subsequent insider sale of the same amount.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   28 Aug 2025, 03:57 UTC

   The analyst published the original source item.

2. First prediction resolved

   30 Sept 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   30 Sept 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 01:22 UTC

   Tahlil Plus began monitoring the extracted predictions.